Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis

Inclusion Criteria: * Male or non-pregnant and non-lactating female, and ≥ 18 years of age. * Diagnosis of angina pectoris or unstable angina pectoris or patients with documented silent ischemia. * Left ventricular ejection fraction ≥30% * Patient has undergone successful and uncomplicated stenting of up to 2 de novo lesions in native coronary arteries OR patient has undergone successful and uncomplicated balloon angioplasty of up to 2 in-stent restenosis (ISR) lesions in native coronary arteries, but not both. * Thrombolysis In Myocardial Infarction (TIMI) 3 coronary flow post-stenting for de novo lesions or post balloon angioplasty for ISR lesions. * No angiographic evidence of thrombus post-procedure. * Target vessel ≥2.5 mm diameter (by angiography). * Each de novo lesion is such that it is stented with ≤ 25 mm of single continuous stent. * Each in-stent restenosis (ISR) lesion is ≤ 25 mm in length. * There is at least 5 mm of non-diseased vessel on either side of target lesion(s). * By intravascular ultrasound (IVUS), stent is fully opposed and has a minimum diameter of 2.5 mm or an in-stent luminal area ≥ 5.0 mm\^2 * Patient or guardian has provided a signed written informed consent to participate in the study and in all follow-up assessments using a form that is approved by the local Institutional Review Board (IRB)/Ethics Committee of the investigative site. Exclusion Criteria: * Target de novo lesion was treated with a drug-eluting stent * Target ISR lesion requires any treatment other than balloon angioplasty * Patient has both a de novo lesion and an ISR lesion. * If more than 2 lesions are treated with percutaneous coronary intervention (PCI), or it is anticipated that additional lesions will require treatment within 2 months. * Previous PCI within preceding two months. * Intended surgical intervention within 6 months of enrollment in the study. * Unprotected left main disease with \>50% stenosis * Malapposition, dissection, or unmasking of a significant narrowing in the inflow or outflow area of the implanted stent. * Women who are pregnant and women of child bearing potential who do not use adequate contraception * Previous participation in another study with any investigational drug or device within the past 30 days or current enrollment in any other clinical protocol or investigational drug or device trial. * Patient has a life expectancy of less than 12 months or there are factors making clinical and/or angiographic follow-up difficult * Any significant medical condition which, in the investigator's opinion, may interfere with the patient's optimal participation in the study * Heart transplant candidate or recipient * Patient is immunosuppressed or is HIV positive. * Patient has experienced a Q wave or a non Q wave myocardial infarction (MI) with documented total creatine kinase (CK) ≥2 times normal within the preceding 24 hours and the CK and creatine kinase-MB fraction (CK-MB) enzymes remain above normal at the time of the procedure. * Cardiogenic shock: sustained systolic blood pressure (SBP) less than 80 mmHg, with no response to fluids or SBP less than 100 mmHg with vasopressors (in absence of bradycardia) * Any individual who may refuse a blood transfusion * Documented major gastro-intestinal bleeding within 3 months * The following lab values at baseline are exclusionary: * Serum creatinine \> 2.5 mg/dl; * Platelet count \< 150,000 cells/mm\^3; * Absolute neutrophil count (ANC) \< 2000 cells/mm\^3; * Hemoglobin (HGB) \<9 g/dl; * Total bilirubin \>1.5 mg/dl; * Alanine Aminotransferase (SGPT) \> 2.5 x upper limit of normal range (ULN); * Aspartate Aminotransferase (SGOT) \> 2.5 x ULN; * Alkaline phosphatase \> 2.5 x ULN. * Known allergy/hypersensitivity/contraindication to the study drug; to any taxanes; or to any required study treatment: aspirin, clopidogrel bisulfate, stent materials * Pre-existing peripheral neuropathy of National Cancer Institute (NCI) Toxicity Grade \> 1.